

Exhibit E

Exhibit E

Summary of BMS/OTN Revenue by Product (\$): Excluding Sales to Federal Entities

Oncology Products

Year	Blenoxane			Cytoxan			Cytoxan Tablets		
	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference
1993	45,649,907	45,127,588	1.1%	1,792,986	(3,969,198)	321.4%	23,818,925	23,709,045	0.5%
1994	41,557,375	40,875,515	1.6%	14,973,816	7,611,340	49.2%	22,794,531	22,599,411	0.9%
1995	45,750,245	44,811,781	2.1%	21,300,057	10,699,500	49.8%	22,589,052	22,359,019	1.0%
1996	42,417,666	39,190,437	7.6%	26,870,955	10,118,920	62.3%	22,226,462	22,029,087	0.9%
1997	33,245,993	24,621,471	25.9%	30,363,888	8,639,477	71.5%	23,092,640	22,981,000	0.5%
1998	29,690,702	19,762,743	33.4%	31,534,561	7,552,518	76.1%	23,926,111	23,867,517	0.2%
1999	36,180,144	23,187,950	35.9%	29,779,171	6,390,282	78.5%	27,254,324	26,669,719	2.1%
2000	27,619,910	15,144,559	45.2%	27,538,022	6,819,271	75.2%	16,191,453	16,089,254	0.6%
2001	16,979,379	7,303,227	57.0%	28,590,256	6,569,617	77.0%	15,920,285	15,799,834	0.8%
2002	12,261,734	5,067,476	58.7%	31,590,911	8,462,788	73.2%	12,146,395	11,182,484	7.9%

Year	Paraplatin			Taxol			VePesid		
	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference
1993	14,281,174	15,862,509	-11.1%				23,183,869	22,715,299	2.0%
1994	115,447,150	113,509,097	1.7%				99,112,667	78,246,790	21.1%
1995	183,911,409	180,224,939	2.0%				111,093,241	68,714,456	38.1%
1996	248,614,036	242,839,711	2.3%				99,599,034	27,770,672	72.1%
1997	321,743,013	313,895,859	2.4%	139,399,280	137,398,468	1.4%	83,652,126	10,804,268	87.1%
1998	405,370,089	396,619,126	2.2%	781,433,996	768,600,523	1.6%	66,732,005	3,376,463	94.9%
1999	472,431,951	461,383,003	2.3%	911,699,756	895,908,869	1.7%	65,868,952	4,359,041	93.4%
2000	576,435,239	563,980,611	2.2%	962,444,588	943,383,975	2.0%	63,264,145	8,228,570	87.0%
2001	598,562,500	579,345,682	3.2%	600,290,626	538,266,068	10.3%	49,357,285	430,087	99.1%
2002	567,058,929	529,580,383	6.6%	220,026,096	36,960,337	83.2%	47,154,659	1,316,996	97.2%

Year	VePesid Capsules		
	Revenue at WLP	Net Revenue	Difference
1993	19,433,818	19,330,376	0.5%
1994	26,764,087	26,622,780	0.5%
1995	25,927,753	25,612,706	1.2%
1996	24,652,321	24,334,034	1.3%
1997	22,610,894	22,504,345	0.5%
1998	27,971,635	27,763,111	0.7%
1999	26,406,692	25,743,112	2.5%
2000	29,491,105	29,072,752	1.4%
2001	22,887,712	22,592,211	1.3%
2002	12,005,950	11,829,980	1.5%

Primary Care/Virology Products

Year	Avapro			Buspar			Cefzil Suspension		
	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference
1993				210,110,583	209,372,976	0.4%	73,921,031	72,771,576	1.6%
1994				258,169,707	256,316,990	0.7%	106,539,800	106,211,140	0.3%
1995				273,271,940	272,005,470	0.5%	113,829,653	113,611,618	0.2%
1996				331,860,366	330,485,629	0.4%	104,477,716	104,168,395	0.3%
1997	17,384,885	17,390,845	0.0%	412,815,613	412,046,123	0.2%	140,626,717	140,332,868	0.2%
1998	82,967,949	82,957,750	0.0%	504,733,509	502,612,414	0.4%	150,169,501	153,659,649	-2.3%
1999	162,748,072	162,943,362	-0.1%	616,168,957	612,187,826	0.6%	169,599,394	166,514,364	1.8%
2000	220,245,669	219,396,260	0.4%	743,402,265	734,987,263	1.1%	183,432,314	176,985,437	3.5%
2001	254,873,810	249,746,506	2.0%	311,056,425	305,697,235	1.7%	160,490,485	156,912,389	2.2%
2002	265,301,023	260,978,799	1.6%	6,388,395	6,380,281	0.1%	65,026,345	63,173,306	2.8%

Year	Cefzil Tablets			Coumadin			Glucophage		
	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference
1993	72,795,393	72,589,551	0.3%						
1994	89,390,675	89,063,178	0.4%						
1995	98,135,898	97,930,356	0.2%				89,782,917	89,723,567	0.1%
1996	110,072,927	109,837,509	0.2%				334,924,760	332,886,589	0.6%
1997	164,914,339	164,382,518	0.3%				571,653,125	568,635,359	0.5%
1998	159,818,643	163,246,435	-2.1%	351,844,525	316,355,367	10.1%	846,568,698	840,328,278	0.7%
1999	192,985,639	188,871,799	2.1%	466,297,095	406,015,752	12.9%	1,254,706,601	1,239,824,091	1.2%
2000	174,226,559	167,821,569	3.7%	298,911,169	228,398,327	23.6%	1,707,405,326	1,690,276,773	1.0%
2001	155,865,218	151,971,166	2.5%	215,438,484	118,935,619	44.8%	2,154,888,818	2,080,092,279	3.5%
2002	47,661,888	46,582,421	2.3%	376,731,314	323,604,029	14.1%	12,705,253	12,286,098	3.3%

Exhibit E

Summary of BMS/OTN Revenue by Product (\$): Excluding Sales to Federal Entities

Year	Glucophage XR			Glucovance			Monopril		
	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference
1993							205,835	205,835	0.0%
1994							5,026,443	4,993,239	0.7%
1995							47,200,779	45,925,622	2.7%
1996							108,653,284	105,452,791	2.9%
1997							159,890,702	158,758,302	0.7%
1998							199,044,489	196,301,019	1.4%
1999							233,578,838	232,102,780	0.6%
2000	58,263,225	52,468,634	9.9%	131,797,451	120,490,699	8.6%	267,914,328	266,749,863	0.4%
2001	337,819,959	329,558,155	2.4%	414,892,075	399,432,856	3.7%	288,472,041	280,066,908	2.9%
2002	266,473,359	260,499,083	2.2%	226,748,635	216,327,990	4.6%	145,044,367	135,165,340	6.8%

Year	Monopril HCT			Plavix			Serzone		
	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference
1993									
1994									
1995							50,509,863	50,501,961	0.0%
1996							95,871,610	95,139,289	0.8%
1997							160,912,997	159,996,051	0.6%
1998				104,900,616	104,871,759	0.0%	223,904,612	222,786,537	0.5%
1999				490,575,620	489,931,884	0.1%	307,990,562	307,402,907	0.2%
2000	7,072,609	6,865,450	2.9%	811,207,539	807,349,396	0.5%	349,718,989	344,892,106	1.4%
2001	18,324,962	18,007,437	1.7%	1,213,543,347	1,190,166,791	1.9%	422,703,882	410,679,857	2.8%
2002	16,902,411	16,450,224	2.7%	1,537,693,579	1,507,723,667	1.9%	145,609,776	135,991,479	6.6%

Year	Tequin			Videx EC		
	Revenue at WLP	Net Revenue	Difference	Revenue at WLP	Net Revenue	Difference
1993						
1994						
1995						
1996						
1997						
1998						
1999	35,631,503	32,140,149	9.8%			
2000	108,121,330	103,907,064	3.9%	20,476,641	19,685,177	3.9%
2001	287,147,062	278,456,352	3.0%	94,812,038	94,594,508	0.2%
2002	97,498,301	93,959,701	3.6%	92,145,585	92,062,294	0.1%

Sources:

BMS invoice data from SHARP:

DirectSales_IncludingPHS.txt
 Pre1997-Direct.txt
 DirectSalesSupplement_Production.txt
 Coumadin Direct Sales_Pre 100197.txt

OTN invoice data:

OTN Blenoxane.txt
 OTN Cytosan.txt
 OTN Paraplatin.txt
 OTN Taxol.txt
 OTN Vepesid.txt
 OTN Blenoxane_Pre1997.txt
 OTN Cytosan_Pre1997.txt
 OTN Paraplatin_Pre1997.txt
 OTN Taxol_Pre1997.txt
 OTN Vepesid_Pre1997.txt

BMS chargeback data:

Chargebacks_IncludingPHS.txt
 Pre1997-Indirect.txt
 ChargebackSupplement_Production.txt
 CoumadinSupplementChbk.txt

Wholesale List Price:

PricingRevised.xls
 buspar_rubex.xls
 WLP PRICING FOR MONTANA MDL.xls

Notes:

Sales and chargebacks to federal government customers are excluded
 Revenue at WLP represents total units sold multiplied by WLP
 Net Revenue is Gross Revenues net of chargebacks
 Difference is Revenue at WLP less Net Revenue, representing price concessions
 See Exhibit D for an explanation of the underlying calculations
 Shaded figures indicate full years in which the drug was patent protected
 Coumadin figures prior to 2002 do not exclude sales to government customers